Such potent effects were associated with decreased cell proliferation and survival of leukemia cells and suppressed leukemic progenitor clonogenicity [89], raising the prospect of using such pan P13’K/AKT/mTOR inhibitors as a potential future approach for the treatment of AML. Here, AKT1 is linked to acute myeloid leukemia.